{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:19:37Z","timestamp":1788261577451,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422068"],"award-info":[{"award-number":["82422068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76339-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:25:59Z","timestamp":1785759959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaohao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongling","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8945-3107","authenticated-orcid":false,"given":"Zheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-6262","authenticated-orcid":false,"given":"Xiaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1603-3223","authenticated-orcid":false,"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-6559","authenticated-orcid":false,"given":"Lingfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"76339_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd2792","volume":"8","author":"A Beenken","year":"2009","unstructured":"Beenken, A. & Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8, 235\u2013253 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76339_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh, M. & Nakagama, H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34, 280\u2013300 (2014).","journal-title":"Med. Res. Rev."},{"key":"76339_CR3","doi-asserted-by":"crossref","unstructured":"Chen, G., Chen, L., Li, X. & Mohammadi, M. FGF-based drug discovery: advances and challenges. Nat. Rev. Drug Discov. 24, 335\u2013357 (2025).","DOI":"10.1038\/s41573-024-01125-w"},{"key":"76339_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jb\/mvq121","volume":"149","author":"N Itoh","year":"2011","unstructured":"Itoh, N. & Ornitz, D. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121\u2013130 (2011).","journal-title":"J. Biochem."},{"key":"76339_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41589-019-0455-7","volume":"16","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat. Chem. Biol. 16, 267\u2013277 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"76339_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","volume":"618","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. Structural basis for FGF hormone signalling. Nature 618, 862\u2013870 (2023).","journal-title":"Nature"},{"key":"76339_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","volume":"16","author":"VP Eswarakumar","year":"2005","unstructured":"Eswarakumar, V. P., Lax, I. & Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139\u2013149 (2005).","journal-title":"Cytokine Growth Factor Rev."},{"key":"76339_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318\u2013332 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"76339_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","volume":"37","author":"M Katoh","year":"2016","unstructured":"Katoh, M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol. Sci. 37, 1081\u20131096 (2016).","journal-title":"Trends Pharmacol. Sci."},{"key":"76339_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","volume":"40","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Fibroblast growth factor receptor fusions in cancer: opportunities and challenges. J. Exp. Clin. Cancer Res. 40, 345 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"76339_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7087","volume":"6","author":"D Sia","year":"2015","unstructured":"Sia, D. et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 6, 6087 (2015).","journal-title":"Nat. Commun."},{"key":"76339_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.tips.2025.09.004","volume":"46","author":"L Chen","year":"2025","unstructured":"Chen, L. Next-generation isoform-selective fibroblast growth factor receptor inhibitors. Trends Pharmacol. Sci. 46, 1091\u20131104 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"76339_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature25451","volume":"553","author":"G Chen","year":"2018","unstructured":"Chen, G. et al. Alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553, 461\u2013466 (2018).","journal-title":"Nature"},{"key":"76339_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature25010","volume":"553","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. Structures of beta-klotho reveal a \u2018zip code\u2019-like mechanism for endocrine FGF signalling. Nature 553, 501\u2013505 (2018).","journal-title":"Nature"},{"key":"76339_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 12, 402\u2013415 (2022).","journal-title":"Cancer Discov."},{"key":"76339_CR16","doi-asserted-by":"crossref","unstructured":"Kommalapati, A., Tella, S.H., Borad, M., Javle, M. & Mahipal, A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers 13, 2968 (2021).","DOI":"10.3390\/cancers13122968"},{"key":"76339_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252\u2013263 (2017).","journal-title":"Cancer Discov."},{"key":"76339_CR18","doi-asserted-by":"publisher","first-page":"175883592095329","DOI":"10.1177\/1758835920953293","volume":"12","author":"A Saborowski","year":"2020","unstructured":"Saborowski, A., Lehmann, U. & Vogel, A. FGFR inhibitors in cholangiocarcinoma: what\u2019s now and what\u2019s next? Ther. Adv. Med. Oncol. 12, 1758835920953293 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"76339_CR19","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio, B. J. et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin. Cancer Res. 29, 4586\u20134595 (2023).","journal-title":"Clin. Cancer Res."},{"key":"76339_CR20","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064\u20131079 (2019).","journal-title":"Cancer Discov."},{"key":"76339_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","volume":"36","author":"L Goyal","year":"2025","unstructured":"Goyal, L. et al. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann. Oncol. 36, 426\u2013443 (2025).","journal-title":"Ann. Oncol."},{"key":"76339_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","volume":"30","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma. Clin. Cancer Res. 30, 198\u2013208 (2024).","journal-title":"Clin. Cancer Res."},{"key":"76339_CR23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","volume":"13","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 13, 2012\u20132031 (2023).","journal-title":"Cancer Discov."},{"key":"76339_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317756121","volume":"121","author":"H Schonherr","year":"2024","unstructured":"Schonherr, H. et al. Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proc. Natl. Acad. Sci. USA 121, e2317756121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76339_CR25","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1158\/2159-8290.CD-23-0728","volume":"13","author":"A Tripathi","year":"2023","unstructured":"Tripathi, A., Li, D. & Pal, S. K. FGFR inhibition: understanding and overcoming resistance. Cancer Discov. 13, 1964\u20131965 (2023).","journal-title":"Cancer Discov."},{"key":"76339_CR26","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-25-4390","volume":"32","author":"F Facchinetti","year":"2026","unstructured":"Facchinetti, F. et al. Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors. Clin. Cancer Res. 32, 1574\u20131587 (2026).","journal-title":"Clin. Cancer Res."},{"key":"76339_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.annonc.2026.01.004","volume":"37","author":"H Ellis","year":"2026","unstructured":"Ellis, H. et al. Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib. Ann. Oncol. 37, 798\u2013812 (2026).","journal-title":"Ann. Oncol."},{"key":"76339_CR28","doi-asserted-by":"publisher","first-page":"e2213090120","DOI":"10.1073\/pnas.2213090120","volume":"120","author":"A Besch","year":"2023","unstructured":"Besch, A., Marsiglia, W. M., Mohammadi, M., Zhang, Y. & Traaseth, N. J. Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state. Proc. Natl. Acad. Sci. USA 120, e2213090120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76339_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"YN Chen","year":"2016","unstructured":"Chen, Y. N. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148\u2013152 (2016).","journal-title":"Nature"},{"key":"76339_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jhep.2018.01.026","volume":"68","author":"A Kabashima","year":"2018","unstructured":"Kabashima, A. et al. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J. Hepatol. 68, 1228\u20131238 (2018).","journal-title":"J. Hepatol."},{"key":"76339_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59318-9","volume":"16","author":"D Chen","year":"2025","unstructured":"Chen, D. et al. Harnessing the FGFR2\/NF2\/YAP signaling-dependent necroptosis to develop an FGFR2\/IL-8 dual blockade therapeutic strategy. Nat. Commun. 16, 4128 (2025).","journal-title":"Nat. Commun."},{"key":"76339_CR32","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1158\/1078-0432.CCR-23-3588","volume":"30","author":"ER Balasooriya","year":"2024","unstructured":"Balasooriya, E. R. et al. The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clin. Cancer Res. 30, 2181\u20132192 (2024).","journal-title":"Clin. Cancer Res."},{"key":"76339_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.molcel.2007.06.028","volume":"27","author":"H Chen","year":"2007","unstructured":"Chen, H. et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 27, 717\u2013730 (2007).","journal-title":"Mol. Cell"},{"key":"76339_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/jbmr.1810","volume":"28","author":"S Wohrle","year":"2013","unstructured":"Wohrle, S. et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J. Bone Miner. Res. 28, 899\u2013911 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"76339_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","volume":"21","author":"M Katoh","year":"2024","unstructured":"Katoh, M. et al. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat. Rev. Clin. Oncol. 21, 312\u2013329 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76339_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","volume":"11","author":"IM Silverman","year":"2021","unstructured":"Silverman, I. M. et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 11, 326\u2013339 (2021).","journal-title":"Cancer Discov."},{"key":"76339_CR37","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1021\/acs.jmedchem.1c01163","volume":"65","author":"LD Turner","year":"2022","unstructured":"Turner, L. D. et al. From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor. J. Med. Chem. 65, 1481\u20131504 (2022).","journal-title":"J. Med. Chem."},{"key":"76339_CR38","doi-asserted-by":"publisher","first-page":"15433","DOI":"10.1021\/acs.jmedchem.2c01366","volume":"65","author":"A Shvartsbart","year":"2022","unstructured":"Shvartsbart, A. et al. Discovery of potent and selective inhibitors of wild-type and gatekeeper mutant fibroblast growth factor receptor (FGFR) 2\/3. J. Med. Chem. 65, 15433\u201315442 (2022).","journal-title":"J. Med. Chem."},{"key":"76339_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116473","volume":"272","author":"H Li","year":"2024","unstructured":"Li, H. et al. Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor. Eur. J. Med. Chem. 272, 116473 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"76339_CR40","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1021\/acs.jmedchem.4c03205","volume":"68","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Discovery of pyrrolopyrazine carboxamide derivatives as potent and selective FGFR2\/3 inhibitors that overcome mutant resistance. J. Med. Chem. 68, 3886\u20133899 (2025).","journal-title":"J. Med. Chem."},{"key":"76339_CR41","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","volume":"66","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer. J. Med. Chem. 66, 7438\u20137453 (2023).","journal-title":"J. Med. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76339-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:02:22Z","timestamp":1788260542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76339"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76339-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9326"}}